You’re doing everything right. You eat healthy, work out, and get decent sleep. Yet that stubborn layer of fat around your midsection just won’t budge. What’s really going on is something called somatopause, which is the age-related decline in growth hormone production. This decline starts around age 30 and continues as you get older, showing up as a decrease in GH pulse amplitude. Every piece of advice you’ve received seems to suggest it’s a matter of willpower. But that’s often not the case. Research points to a key upstream cause: reduced output of GHRH, the signal from the hypothalamus that prompts the pituitary to release GH. The pituitary gland still has the ability to respond. It’s just getting a weaker signal than before. This decline hits hardest in one specific area: Visceral fat, the fat surrounding your organs. This type of fat has a higher concentration of GH receptors. It also breaks down at a higher rate compared to fat in other parts of the body. So when GH levels drop, visceral fat, the kind most associated with insulin resistance, inflammation, and heart disease, is usually the first impacted. If the problem starts with a weakened GHRH signal, the more direct fix is to restore that signal, rather than replace GH itself. This is where tesamorelin comes in.
Tesamorelin’s off-label use for visceral fat
Tesamorelin is a GHRH analog, a lab-made version of the signal itself, rather than just synthetic growth hormone injected directly. It sends the message back to your pituitary to produce GH, allowing your pituitary to still control how much is released, while keeping the normal feedback loops that regulate GH intact. This means the release remains pulsatile, mimicking the natural process, instead of the constant elevated levels that come from direct HGH injections. Tesamorelin was created by Theratechnologies and got FDA approval back in 2010 under the brand name Egrifta. It was specifically for HIV-related lipodystroph, with many on the internet searching for, ‘tesamorelin for visceral fat’. This condition happens when antiretroviral therapy causes fat to shift in weird ways, leading to a buildup of fat in the abdomen while the face and limbs lose it. The drug has also completed Phase 3 trials. The findings were validated through CT scans rather than just depending on self-reports, which sets a higher bar for evidence compared to much of what’s found in the peptide market. It’s crucial to point out that the most trustworthy data comes from HIV patients, not just the general aging population. The off-label use for visceral fat is increasing, and the biological mechanism fits well with wider applications. However, we still don’t have direct evidence beyond that specific group. Monitoring is key as well. We should keep track of IGF-1 and glucose tolerance levels. This drug isn’t recommended for anyone with active or recent cancer, since it raises IGF-1, a hormone whose impact on tumor growth remains uncertain. If you’ve been tackling that stubborn belly fat as if it’s just a matter of willpower, it’s good to know there’s a specific hormonal signal working against you, and there’s a compound with real clinical trial data that aims to restore the signal your body used to send naturally.